ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Hepatitis B Vaccine (Recombinant) Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-37V7715
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Hepatitis B Vaccine Recombinant Market Insights and Forecast to 2028
BUY CHAPTERS

Global Hepatitis B Vaccine (Recombinant) Market Research Report 2025

Code: QYRE-Auto-37V7715
Report
July 2025
Pages:84
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
GSK
Merck
Sanofi Pasteur
Dynavax Technologies
LG Life Sciences
KM Biologics
Shenzhen Kangtai Biological Products
Serum Institute

Hepatitis B Vaccine (Recombinant) Market Size

The global market for Hepatitis B Vaccine (Recombinant) was valued at US$ 1088 million in the year 2024 and is projected to reach a revised size of US$ 1343 million by 2031, growing at a CAGR of 3.1% during the forecast period.

Hepatitis B Vaccine (Recombinant) Market

Hepatitis B Vaccine (Recombinant) Market

Hepatitis B vaccine is a vaccine that prevents hepatitis B.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Hepatitis B Vaccine (Recombinant), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis B Vaccine (Recombinant).
The Hepatitis B Vaccine (Recombinant) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hepatitis B Vaccine (Recombinant) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hepatitis B Vaccine (Recombinant) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Hepatitis B Vaccine (Recombinant) Market Report

Report Metric Details
Report Name Hepatitis B Vaccine (Recombinant) Market
Accounted market size in year US$ 1088 million
Forecasted market size in 2031 US$ 1343 million
CAGR 3.1%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • 10mcg/0.5ml
  • 10mcg/ml
Segment by Application
  • Newborn
  • Adult
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company GSK, Merck, Sanofi Pasteur, Dynavax Technologies, LG Life Sciences, KM Biologics, Shenzhen Kangtai Biological Products, Serum Institute
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Hepatitis B Vaccine (Recombinant) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Hepatitis B Vaccine (Recombinant) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Hepatitis B Vaccine (Recombinant) Market growing?

Ans: The Hepatitis B Vaccine (Recombinant) Market witnessing a CAGR of 3.1% during the forecast period 2025-2031.

What is the Hepatitis B Vaccine (Recombinant) Market size in 2031?

Ans: The Hepatitis B Vaccine (Recombinant) Market size in 2031 will be US$ 1343 million.

Who are the main players in the Hepatitis B Vaccine (Recombinant) Market report?

Ans: The main players in the Hepatitis B Vaccine (Recombinant) Market are GSK, Merck, Sanofi Pasteur, Dynavax Technologies, LG Life Sciences, KM Biologics, Shenzhen Kangtai Biological Products, Serum Institute

What are the Application segmentation covered in the Hepatitis B Vaccine (Recombinant) Market report?

Ans: The Applications covered in the Hepatitis B Vaccine (Recombinant) Market report are Newborn, Adult

What are the Type segmentation covered in the Hepatitis B Vaccine (Recombinant) Market report?

Ans: The Types covered in the Hepatitis B Vaccine (Recombinant) Market report are 10mcg/0.5ml, 10mcg/ml

Recommended Reports

Human Viral Vaccines

Hepatitis and Liver

Vaccine Technology

1 Hepatitis B Vaccine (Recombinant) Market Overview
1.1 Product Definition
1.2 Hepatitis B Vaccine (Recombinant) by Type
1.2.1 Global Hepatitis B Vaccine (Recombinant) Market Value Comparison by Type (2024 VS 2031)
1.2.2 10mcg/0.5ml
1.2.3 10mcg/ml
1.3 Hepatitis B Vaccine (Recombinant) by Application
1.3.1 Global Hepatitis B Vaccine (Recombinant) Market Value by Application (2024 VS 2031)
1.3.2 Newborn
1.3.3 Adult
1.4 Global Hepatitis B Vaccine (Recombinant) Market Size Estimates and Forecasts
1.4.1 Global Hepatitis B Vaccine (Recombinant) Revenue 2020-2031
1.4.2 Global Hepatitis B Vaccine (Recombinant) Sales 2020-2031
1.4.3 Global Hepatitis B Vaccine (Recombinant) Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Hepatitis B Vaccine (Recombinant) Market Competition by Manufacturers
2.1 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Manufacturers (2020-2025)
2.2 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Hepatitis B Vaccine (Recombinant) Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Hepatitis B Vaccine (Recombinant), Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Hepatitis B Vaccine (Recombinant), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hepatitis B Vaccine (Recombinant), Product Type & Application
2.7 Global Key Manufacturers of Hepatitis B Vaccine (Recombinant), Date of Enter into This Industry
2.8 Global Hepatitis B Vaccine (Recombinant) Market Competitive Situation and Trends
2.8.1 Global Hepatitis B Vaccine (Recombinant) Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Hepatitis B Vaccine (Recombinant) Players Market Share by Revenue
2.8.3 Global Hepatitis B Vaccine (Recombinant) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Hepatitis B Vaccine (Recombinant) Market Scenario by Region
3.1 Global Hepatitis B Vaccine (Recombinant) Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Hepatitis B Vaccine (Recombinant) Sales by Region: 2020-2031
3.2.1 Global Hepatitis B Vaccine (Recombinant) Sales by Region: 2020-2025
3.2.2 Global Hepatitis B Vaccine (Recombinant) Sales by Region: 2026-2031
3.3 Global Hepatitis B Vaccine (Recombinant) Revenue by Region: 2020-2031
3.3.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Region: 2020-2025
3.3.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Region: 2026-2031
3.4 North America Hepatitis B Vaccine (Recombinant) Market Facts & Figures by Country
3.4.1 North America Hepatitis B Vaccine (Recombinant) Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Hepatitis B Vaccine (Recombinant) Sales by Country (2020-2031)
3.4.3 North America Hepatitis B Vaccine (Recombinant) Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Hepatitis B Vaccine (Recombinant) Market Facts & Figures by Country
3.5.1 Europe Hepatitis B Vaccine (Recombinant) Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2020-2031)
3.5.3 Europe Hepatitis B Vaccine (Recombinant) Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hepatitis B Vaccine (Recombinant) Market Facts & Figures by Region
3.6.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Region (2020-2031)
3.6.3 Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Hepatitis B Vaccine (Recombinant) Market Facts & Figures by Country
3.7.1 Latin America Hepatitis B Vaccine (Recombinant) Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Hepatitis B Vaccine (Recombinant) Sales by Country (2020-2031)
3.7.3 Latin America Hepatitis B Vaccine (Recombinant) Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Facts & Figures by Country
3.8.1 Middle East and Africa Hepatitis B Vaccine (Recombinant) Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Country (2020-2031)
3.8.3 Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Hepatitis B Vaccine (Recombinant) Sales by Type (2020-2031)
4.1.1 Global Hepatitis B Vaccine (Recombinant) Sales by Type (2020-2025)
4.1.2 Global Hepatitis B Vaccine (Recombinant) Sales by Type (2026-2031)
4.1.3 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type (2020-2031)
4.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Type (2020-2031)
4.2.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Type (2020-2025)
4.2.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Type (2026-2031)
4.2.3 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Type (2020-2031)
4.3 Global Hepatitis B Vaccine (Recombinant) Price by Type (2020-2031)
5 Segment by Application
5.1 Global Hepatitis B Vaccine (Recombinant) Sales by Application (2020-2031)
5.1.1 Global Hepatitis B Vaccine (Recombinant) Sales by Application (2020-2025)
5.1.2 Global Hepatitis B Vaccine (Recombinant) Sales by Application (2026-2031)
5.1.3 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application (2020-2031)
5.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Application (2020-2031)
5.2.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Application (2020-2025)
5.2.2 Global Hepatitis B Vaccine (Recombinant) Revenue by Application (2026-2031)
5.2.3 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Application (2020-2031)
5.3 Global Hepatitis B Vaccine (Recombinant) Price by Application (2020-2031)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Company Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2020-2025)
6.1.4 GSK Hepatitis B Vaccine (Recombinant) Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Merck
6.2.1 Merck Company Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Merck Hepatitis B Vaccine (Recombinant) Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Sanofi Pasteur
6.3.1 Sanofi Pasteur Company Information
6.3.2 Sanofi Pasteur Description and Business Overview
6.3.3 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Product Portfolio
6.3.5 Sanofi Pasteur Recent Developments/Updates
6.4 Dynavax Technologies
6.4.1 Dynavax Technologies Company Information
6.4.2 Dynavax Technologies Description and Business Overview
6.4.3 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Product Portfolio
6.4.5 Dynavax Technologies Recent Developments/Updates
6.5 LG Life Sciences
6.5.1 LG Life Sciences Company Information
6.5.2 LG Life Sciences Description and Business Overview
6.5.3 LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2020-2025)
6.5.4 LG Life Sciences Hepatitis B Vaccine (Recombinant) Product Portfolio
6.5.5 LG Life Sciences Recent Developments/Updates
6.6 KM Biologics
6.6.1 KM Biologics Company Information
6.6.2 KM Biologics Description and Business Overview
6.6.3 KM Biologics Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2020-2025)
6.6.4 KM Biologics Hepatitis B Vaccine (Recombinant) Product Portfolio
6.6.5 KM Biologics Recent Developments/Updates
6.7 Shenzhen Kangtai Biological Products
6.7.1 Shenzhen Kangtai Biological Products Company Information
6.7.2 Shenzhen Kangtai Biological Products Description and Business Overview
6.7.3 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Product Portfolio
6.7.5 Shenzhen Kangtai Biological Products Recent Developments/Updates
6.8 Serum Institute
6.8.1 Serum Institute Company Information
6.8.2 Serum Institute Description and Business Overview
6.8.3 Serum Institute Hepatitis B Vaccine (Recombinant) Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Serum Institute Hepatitis B Vaccine (Recombinant) Product Portfolio
6.8.5 Serum Institute Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hepatitis B Vaccine (Recombinant) Industry Chain Analysis
7.2 Hepatitis B Vaccine (Recombinant) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hepatitis B Vaccine (Recombinant) Production Mode & Process Analysis
7.4 Hepatitis B Vaccine (Recombinant) Sales and Marketing
7.4.1 Hepatitis B Vaccine (Recombinant) Sales Channels
7.4.2 Hepatitis B Vaccine (Recombinant) Distributors
7.5 Hepatitis B Vaccine (Recombinant) Customer Analysis
8 Hepatitis B Vaccine (Recombinant) Market Dynamics
8.1 Hepatitis B Vaccine (Recombinant) Industry Trends
8.2 Hepatitis B Vaccine (Recombinant) Market Drivers
8.3 Hepatitis B Vaccine (Recombinant) Market Challenges
8.4 Hepatitis B Vaccine (Recombinant) Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
GSK
Merck
Sanofi Pasteur
Dynavax Technologies
LG Life Sciences
KM Biologics
Shenzhen Kangtai Biological Products
Serum Institute
List of Tables
 Table 1. Global Hepatitis B Vaccine (Recombinant) Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Hepatitis B Vaccine (Recombinant) Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Hepatitis B Vaccine (Recombinant) Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Hepatitis B Vaccine (Recombinant) Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Hepatitis B Vaccine (Recombinant) Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Hepatitis B Vaccine (Recombinant) Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Hepatitis B Vaccine (Recombinant) Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Hepatitis B Vaccine (Recombinant), Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Hepatitis B Vaccine (Recombinant), Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Hepatitis B Vaccine (Recombinant), Product Type & Application
 Table 12. Global Key Manufacturers of Hepatitis B Vaccine (Recombinant), Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Hepatitis B Vaccine (Recombinant) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatitis B Vaccine (Recombinant) as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Hepatitis B Vaccine (Recombinant) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Hepatitis B Vaccine (Recombinant) Sales by Region (2020-2025) & (K Units)
 Table 18. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Region (2020-2025)
 Table 19. Global Hepatitis B Vaccine (Recombinant) Sales by Region (2026-2031) & (K Units)
 Table 20. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Region (2026-2031)
 Table 21. Global Hepatitis B Vaccine (Recombinant) Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Region (2020-2025)
 Table 23. Global Hepatitis B Vaccine (Recombinant) Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Region (2026-2031)
 Table 25. North America Hepatitis B Vaccine (Recombinant) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Hepatitis B Vaccine (Recombinant) Sales by Country (2020-2025) & (K Units)
 Table 27. North America Hepatitis B Vaccine (Recombinant) Sales by Country (2026-2031) & (K Units)
 Table 28. North America Hepatitis B Vaccine (Recombinant) Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Hepatitis B Vaccine (Recombinant) Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Hepatitis B Vaccine (Recombinant) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Hepatitis B Vaccine (Recombinant) Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Hepatitis B Vaccine (Recombinant) Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Hepatitis B Vaccine (Recombinant) Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Hepatitis B Vaccine (Recombinant) Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Hepatitis B Vaccine (Recombinant) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Hepatitis B Vaccine (Recombinant) Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Hepatitis B Vaccine (Recombinant) Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Hepatitis B Vaccine (Recombinant) Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Hepatitis B Vaccine (Recombinant) Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Hepatitis B Vaccine (Recombinant) Sales (K Units) by Type (2020-2025)
 Table 51. Global Hepatitis B Vaccine (Recombinant) Sales (K Units) by Type (2026-2031)
 Table 52. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type (2020-2025)
 Table 53. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Type (2026-2031)
 Table 54. Global Hepatitis B Vaccine (Recombinant) Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Hepatitis B Vaccine (Recombinant) Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Type (2020-2025)
 Table 57. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Type (2026-2031)
 Table 58. Global Hepatitis B Vaccine (Recombinant) Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Hepatitis B Vaccine (Recombinant) Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Hepatitis B Vaccine (Recombinant) Sales (K Units) by Application (2020-2025)
 Table 61. Global Hepatitis B Vaccine (Recombinant) Sales (K Units) by Application (2026-2031)
 Table 62. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application (2020-2025)
 Table 63. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Application (2026-2031)
 Table 64. Global Hepatitis B Vaccine (Recombinant) Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Hepatitis B Vaccine (Recombinant) Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Application (2020-2025)
 Table 67. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Application (2026-2031)
 Table 68. Global Hepatitis B Vaccine (Recombinant) Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Hepatitis B Vaccine (Recombinant) Price (US$/Unit) by Application (2026-2031)
 Table 70. GSK Company Information
 Table 71. GSK Description and Business Overview
 Table 72. GSK Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. GSK Hepatitis B Vaccine (Recombinant) Product
 Table 74. GSK Recent Developments/Updates
 Table 75. Merck Company Information
 Table 76. Merck Description and Business Overview
 Table 77. Merck Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Merck Hepatitis B Vaccine (Recombinant) Product
 Table 79. Merck Recent Developments/Updates
 Table 80. Sanofi Pasteur Company Information
 Table 81. Sanofi Pasteur Description and Business Overview
 Table 82. Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Product
 Table 84. Sanofi Pasteur Recent Developments/Updates
 Table 85. Dynavax Technologies Company Information
 Table 86. Dynavax Technologies Description and Business Overview
 Table 87. Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Dynavax Technologies Hepatitis B Vaccine (Recombinant) Product
 Table 89. Dynavax Technologies Recent Developments/Updates
 Table 90. LG Life Sciences Company Information
 Table 91. LG Life Sciences Description and Business Overview
 Table 92. LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. LG Life Sciences Hepatitis B Vaccine (Recombinant) Product
 Table 94. LG Life Sciences Recent Developments/Updates
 Table 95. KM Biologics Company Information
 Table 96. KM Biologics Description and Business Overview
 Table 97. KM Biologics Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. KM Biologics Hepatitis B Vaccine (Recombinant) Product
 Table 99. KM Biologics Recent Developments/Updates
 Table 100. Shenzhen Kangtai Biological Products Company Information
 Table 101. Shenzhen Kangtai Biological Products Description and Business Overview
 Table 102. Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Product
 Table 104. Shenzhen Kangtai Biological Products Recent Developments/Updates
 Table 105. Serum Institute Company Information
 Table 106. Serum Institute Description and Business Overview
 Table 107. Serum Institute Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Serum Institute Hepatitis B Vaccine (Recombinant) Product
 Table 109. Serum Institute Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. Hepatitis B Vaccine (Recombinant) Distributors List
 Table 113. Hepatitis B Vaccine (Recombinant) Customers List
 Table 114. Hepatitis B Vaccine (Recombinant) Market Trends
 Table 115. Hepatitis B Vaccine (Recombinant) Market Drivers
 Table 116. Hepatitis B Vaccine (Recombinant) Market Challenges
 Table 117. Hepatitis B Vaccine (Recombinant) Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Hepatitis B Vaccine (Recombinant)
 Figure 2. Global Hepatitis B Vaccine (Recombinant) Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Hepatitis B Vaccine (Recombinant) Market Share by Type: 2024 & 2031
 Figure 4. 10mcg/0.5ml Product Picture
 Figure 5. 10mcg/ml Product Picture
 Figure 6. Global Hepatitis B Vaccine (Recombinant) Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Hepatitis B Vaccine (Recombinant) Market Share by Application: 2024 & 2031
 Figure 8. Newborn
 Figure 9. Adult
 Figure 10. Global Hepatitis B Vaccine (Recombinant) Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Hepatitis B Vaccine (Recombinant) Market Size (2020-2031) & (US$ Million)
 Figure 12. Global Hepatitis B Vaccine (Recombinant) Sales (2020-2031) & (K Units)
 Figure 13. Global Hepatitis B Vaccine (Recombinant) Average Price (US$/Unit) & (2020-2031)
 Figure 14. Hepatitis B Vaccine (Recombinant) Report Years Considered
 Figure 15. Hepatitis B Vaccine (Recombinant) Sales Share by Manufacturers in 2024
 Figure 16. Global Hepatitis B Vaccine (Recombinant) Revenue Share by Manufacturers in 2024
 Figure 17. Global 5 and 10 Largest Hepatitis B Vaccine (Recombinant) Players: Market Share by Revenue in Hepatitis B Vaccine (Recombinant) in 2024
 Figure 18. Hepatitis B Vaccine (Recombinant) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 19. Global Hepatitis B Vaccine (Recombinant) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 20. North America Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2020-2031)
 Figure 21. North America Hepatitis B Vaccine (Recombinant) Revenue Market Share by Country (2020-2031)
 Figure 22. U.S. Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 23. Canada Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Europe Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2020-2031)
 Figure 25. Europe Hepatitis B Vaccine (Recombinant) Revenue Market Share by Country (2020-2031)
 Figure 26. Germany Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. France Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. U.K. Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Italy Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Russia Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Asia Pacific Hepatitis B Vaccine (Recombinant) Sales Market Share by Region (2020-2031)
 Figure 32. Asia Pacific Hepatitis B Vaccine (Recombinant) Revenue Market Share by Region (2020-2031)
 Figure 33. China Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Japan Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. South Korea Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. India Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Australia Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Taiwan Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Indonesia Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Thailand Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Malaysia Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Philippines Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Hepatitis B Vaccine (Recombinant) Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Hepatitis B Vaccine (Recombinant) Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Hepatitis B Vaccine (Recombinant) Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Hepatitis B Vaccine (Recombinant) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Hepatitis B Vaccine (Recombinant) by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Hepatitis B Vaccine (Recombinant) by Type (2020-2031)
 Figure 55. Global Hepatitis B Vaccine (Recombinant) Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Hepatitis B Vaccine (Recombinant) by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Hepatitis B Vaccine (Recombinant) by Application (2020-2031)
 Figure 58. Global Hepatitis B Vaccine (Recombinant) Price (US$/Unit) by Application (2020-2031)
 Figure 59. Hepatitis B Vaccine (Recombinant) Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Recombinant Hepatitis B Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hepatitis Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Mono Hepatitis Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hepatitis A and B Combined Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hepatitis B Vaccines Market
Global Hepatitis B Vaccination Market Research Report 2025
Mono Hepatitis B Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Recombinant DNA Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hepatitis A and B Vaccine Market Research Report 2025
Global Hepatitis A and B Vaccination Market Research Report 2025
Global DNA Vaccines Market Insights Forecast to 2030
RSV Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Mono Hepatitis A Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hepatitis B Infectious Disease Tests Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hepatitis B Treatment Market Insights Forecast to 2030
Global Recombinant Vector Vaccines Market Insights Forecast to 2030
Global Hepatitis A Vaccination Market Research Report 2025
Global Recombinant Hamster Ovary Cell CHO Hepatitis B Vaccine Market Insights Forecast to 2030
Global Recombinant Protein Vaccine Market Insights Forecast to 2030
Poliovirus Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Hepatitis B Virus Core Antibody Diagnostic Kits Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-21N6899
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Pediatric Vaccines Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13M6952
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Poliomyelitis Vaccines Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29X7355
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Varicella Virus (Chickenpox) Vaccine Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28B293
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions